Clinical trials: Adjuvant Treatment
Chronic Intracranial Subdural Hematoma
Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas
The chronic subdural hematoma is a common disease in the population over 60 years. For example, in patients over 70 years, it occurs every year 7 new cases per 100,000 people.
- Trial name
- hemacort (NCT01380028)
- Testing
- oral corticosteroids
- Where
- France
- Volunteers
- 162 people
- Sponsor
- University Hospital, Montpellier
Triple Negative Breast Cancer
Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy
Breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide. According to specific clinical, molecular and genetic characteristics of patients, breast cancer is distinguished into…
- Trial name
- NCT07820228
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Chemotherapy-Induced Neutropenia
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid…
- Trial name
- VISTA (NCT02454530)
- Testing
- Nivestim®
- Where
- 92 sites in France
- Volunteers
- 1,160 people
- Sponsor
- Pfizer
Sickle Cell Disease
L-Arginine and Sickle Cell Disease
One of the main problems in sickle cell disease is the decreased bioavailability of nitric oxide and arginine. This study was designed to assess if treating sickle cell disease patients with L-arginine would improve pulmonary…
- Trial name
- NCT01142219
- Testing
- L-arginine
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Epidermal Growth Factor, Nd-yttrium Aluminum Garnet Laser
Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines
Subjects were randomly assigned to groups for treatment with either an EGF-containing ointment (the study group) or the vehicle alone (petrolatum; the control group). The EGF ointment included recombinant human EGF (1 μg/g).
- Conditions
- Epidermal Growth Factor, Nd-yttrium Aluminum Garnet Laser, Hyperpigmentation, Post Inflammatory Hyperpigmentation
- Trial name
- NCT04704245
- Testing
- epidermal growth factor (EGF)-containing ointment, Vehicle ointment, Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hallym University Kangnam Sacred Heart Hospital
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02042430
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
Healthy
Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine
The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune…
- Trial name
- VSG-2011-101 (NCT01578070)
- Testing
- 0.2μg Act-HIB®, ViscoGel® and 0.2μg Act-HIB®, ViscoGel® and 2μg Act-HIB®
- Where
- Sweden
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Viscogel AB
Prostate Cancer
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer.
- Trial name
- NCT00305669
- Testing
- sargramostim, immunohistochemistry staining method, immunological diagnostic method
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Neoplasms, Breast
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone…
- Trial name
- ALTTO (NCT00490139)
- Testing
- Lapatinib, Trastuzumab
- Where
- 924 sites in United States, Argentina and 42 more
- Volunteers
- 8,381 people
- Sponsor
- Novartis Pharmaceuticals
Abortion, Second Trimester
Induction of Abortion in the Second Trimester
To compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
- Trial name
- NCT06207539
- Testing
- hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company, misoprostol under the generic name of misotac tablets
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ain Shams Maternity Hospital
HER2/Neu Positive, Progesterone Receptor Positive
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01275677
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 1,283 sites in United States, Canada and 2 more
- Volunteers
- 3,270 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
This is a a multicenter, randomized, controlled, phase III trial comparing High-Dose IFN-a2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma.The study objective is to compare efficacy…
- Trial name
- NCT03435302
- Testing
- Temozolomide Plus Cisplatin, High-Dose IFN-a2b
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells.
- Trial name
- NCT00006470
- Testing
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
- Where
- 237 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Pneumonitis, Immune-related Adverse Event
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
The introduction of immune checkpoint inhibitors (immunotherapy) that stimulate our immune system to recognize and attack cancer cells has been one of the most exciting advances in oncology over the last decade.
- Trial name
- NCT06860542
- Testing
- Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care, Arm 1- Usual care
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Combination Chemotherapy in Treating Women With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery.
- Trial name
- NCT00033683
- Testing
- CMF regimen, cyclophosphamide, docetaxel
- Where
- 69 sites in Belgium, United Kingdom
- Sponsor
- Institute of Cancer Research, United Kingdom
Sarcoma
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) either for 12 or for 36 months following surgery.
- Trial name
- NCT00116935
- Testing
- imatinib mesylate, imatinib
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Scandinavian Sarcoma Group
Kidney Cancer
Lymphocyte Therapy in Treating Patients With Kidney Cancer
RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body.
- Trial name
- NCT00002589
- Testing
- aldesleukin, muromonab-CD3, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of the Cervix, Conization of the Cervix
Predicting Adjuvant Post-operative Radiation Therapy in Patients With Cervical Cancer Stage IB2
A pre- operative evaluation for the presence of intermediate risk factors prior to surgery may allow for better patient counselling, modify the course of surgery or select patients to undergo primary chemo- radiation.
- Conditions
- Cancer of the Cervix, Conization of the Cervix, Radiation Therapy
- Trial name
- NCT04868097
- Testing
- cervix biopsy
- Where
- Israel
- Volunteers
- 52 people
- Sponsor
- Kaplan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.